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Introduction/Objectives: In 2001, Croatia had 
4,437,460 inhabitants and 15.7% were older than 65 
years. Th e same source of information registered 1,455 
persons between 95 and 108 years of age. In the da-
tabase of the Croatian Institute for Health Insurance, 
806,070 persons older than 65 years were registered 
in December 2006. Th e newest estimate for the Croa-
tian population, from July 2009, is 4,489,409. Life 
expectancy at birth is estimated to be 79 years for the 
female population and 72 years for the male popula-
tion. Demographic trends observed over the past 5-6 
decades show depopulation, and the overall popula-
tion getting older. An extrapolation of these data to 
the year 2050 predicts 26.2% of people older than 65 
years. Th e above data place Croatia among the oldest 
populations among European countries.
Participants, Materials/Methods: Croatia has no 
register of persons with dementia (PWD). If 10% of 
people above 65 years of age are aff ected by dementia, 
the number of PWD would be about 80,000, the ma-
jority being patients with Alzheimer’s disease (AD). 
It is assessed that up to 15,000 PWD live in Zagreb, 
the capital of Croatia.
Five drugs are currently approved by the United 
States Food and Drug Administration (FDA) for the 
treatment of PWD. All fi ve drugs are recommended 
for use in Croatia, but only three are registered in 
Croatia. However, none of the three is on the reim-
bursement list of the Croatian Institute for Health 
Insurance. Due to the high cost of these drugs, the 
majority of PWD cannot aff ord to buy these drugs.
Results: In connection with above mentioned 
some of the patients undergo clinical trials and are 
treated with investigational agents which, if they are 
lucky, may be adequate treatment for them, but usu-
ally with short or limited duration.
Clinical studies of new antidementia drugs have 
been conducted in Croatia since 1989, and some 
PWD participating in these studies benefi t directly 
from them. Th e trials began with pentoxifylline and 
continued with propentofylline, donepezil, phenser-
ine-tartrate and EVP-6124. Clinical trials will in-
clude some novel potential antidementia agents in the 
near future.
Conclusions: Inform consent for clinical trial ob-
tained from person with Alzheimer’s disease ia a valid 
and useful piece of evidence in evaluation of post-mor-
tem competency. Naimely, this document is signed by 
patient personally and represents ability of person to 
understand the scope and procedure of protocol and 
actively participate in one complex process.
